Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial-Reference-Cited by-同舟云学术

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Published:2017-02-22 Issue:1 Volume:10 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Verstovsek Srdan, ,Mesa Ruben A.,Gotlib Jason,Gupta Vikas,DiPersio John F.,Catalano John V.,Deininger Michael W. N.,Miller Carole B.,Silver Richard T.,Talpaz Moshe,Winton Elliott F.,Harvey Jimmie H.,Arcasoy Murat O.,Hexner Elizabeth O.,Lyons Roger M.,Paquette Ronald,Raza Azra,Jones Mark,Kornacki Deanna,Sun Kang,Kantarjian Hagop

Funder

Incyte Corporation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-017-0417-z.pdf

Reference27 articles.

1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

2. Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167.

3. Pardanani A, Guglielmelli P, Lasho TL, Pancrazzi A, Finke CM, Vannucchi AM, et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia. 2011;25:1834–9.